ArticleInternational journal of nanomedicine2026
Continuous Coagulation Monitoring in Human Blood Samples via Magnetic Particle Spectroscopy.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Magnetic Particle Imaging (MPI) is a radiation-free imaging modality based on the nonlinear magnetic response of iron oxide nanoparticles, providing high sensitivity and real-time, quantitative, background-free imaging. With the clinical approval of Resotran as an MPI-suitable tracer and the development of first human-scale scanners, clinical applications are within reach. Magnetic Particle Spectroscopy (MPS), the non-imaging counterpart of MPI, enables sensitive analytics by exploiting the signal response of magnetic nanoparticles. In this pilot study, we prove the potential of MPS to continuously monitor blood coagulation in real time. Methods: Blood samples from five volunteers were mixed with the commercial magnetic resonance imaging contrast agent Resotran. The dynamics of the particle signal were assessed in a custom-built MPS-system for a duration of 45 minutes under various conditions, including the presence of anticoagulants (EDTA, Heparin, Citrate) and mechanical stress. The signal amplitude of the fifth harmonic of the MPS was analyzed. To exclude potential thermal effects, the temperature inside the MPS was monitored by using a fiber optic thermometer during the measurements. Results: All Resotran-containing blood samples showed a signal decrease over time. Samples with anticoagulants exhibited no relevant signal decrease (EDTA, Citrate) or a smaller decrease (Heparin) compared to samples without anticoagulants. Additionally, mechanical stress induced a signal decay in all samples, further indicating the link between the observed MPS signal decay and blood coagulation. Conclusion: This study shows that continuous monitoring of human blood coagulation via MPS is feasible, making bedside coagulation monitoring in clinical settings a concrete perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.